GL9 logo

Glanbia plc Stock Price

ISE:GL9 Community·€5.2b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author

GL9 Share Price Performance

€21.70
9.08 (71.95%)
€20.58
Fair Value
€21.70
9.08 (71.95%)
5.4% overvalued intrinsic discount
€20.58
Fair Value
Price €21.70
AnalystConsensusTarget €20.58
AnalystLowTarget €15.63
AnalystHighTarget €22.60

GL9 Community Narratives

·
Fair Value €20.58 5.4% overvalued intrinsic discount

Expanding Health And Dairy Nutrition Will Unlock Global Demand

0users have liked this narrative
1users have commented on this narrative
16users have followed this narrative
·
Fair Value €15.63 38.8% overvalued intrinsic discount

Plant-based Trends And ESG Pressures Will Weaken Dairy Demand

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value €22.6 4.0% undervalued intrinsic discount

Digital And Plant Based Nutrition Will Expand Global Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
€22.6
4.0% undervalued intrinsic discount
Revenue
4.26% p.a.
Profit Margin
9.23%
Future PE
15.97x
Price in 2029
€27.07
€20.58
5.4% overvalued intrinsic discount
Revenue
3.57% p.a.
Profit Margin
9.25%
Future PE
14.77x
Price in 2029
€24.65
€15.63
38.8% overvalued intrinsic discount
Revenue
2.62% p.a.
Profit Margin
8.23%
Future PE
13.13x
Price in 2029
€18.64

Trending Discussion

Updated Narratives

GL9 logo

GL9: Refined Earnings And Margin Assumptions Will Guide Share Price Direction

Fair Value: €22.6 4.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
GL9 logo

GL9: Capital Returns And Whey Input Costs Will Shape Future Share Performance

Fair Value: €20.58 5.4% overvalued intrinsic discount
16 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative
GL9 logo

GL9: Whey Cost Pressures And Capital Returns Will Shape A Balanced Outlook

Fair Value: €15.63 38.8% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with proven track record and pays a dividend.

3 Risks
3 Rewards

Glanbia plc Key Details

US$3.9b

Revenue

US$2.9b

Cost of Revenue

US$1.1b

Gross Profit

US$878.3m

Other Expenses

US$183.3m

Earnings

Last Reported Earnings
Jan 03, 2026
Next Reporting Earnings
Aug 06, 2026
0.76
26.90%
4.64%
52.8%
View Full Analysis

About GL9

Founded
1964
Employees
4963
CEO
Hugh McGuire
WebsiteView website
www.glanbia.com

Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing business; property and land dealing business; property leasing; provision of business services and management solutions; and bioactive solutions. It offers its products under the Optimum Nutrition, BSN, Isopure, Nutramino, think!, Amazing Grass brands. The company sells its products through specialty retail, online, gym, and food, drug, mass, and club channels. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.

Recent GL9 News & Updates

Narrative Update Jun 03

GL9: Refined Earnings And Margin Assumptions Will Guide Share Price Direction

The analyst fair value estimate for Glanbia has moved from €20.45 to €22.60, reflecting updated views on revenue growth, margins and valuation after several recent price target adjustments from banks including Deutsche Bank, Morgan Stanley and Mizuho. Analysts broadly point to refined assumptions on the company’s earnings power and appropriate future P/E.
Narrative Update May 20

GL9: Capital Returns And Whey Input Costs Will Shape Future Share Performance

Glanbia's updated analyst price target has moved from €19.44 to €20.58, reflecting analysts' revised views on margins, growth assumptions and P/E expectations following recent mixed target changes from Morgan Stanley, Deutsche Bank and Mizuho, alongside downgrades from Kepler Cheuvreux and Morgan Stanley. Analyst Commentary Recent research updates on Glanbia present a mix of optimism and caution, with investors weighing improved price targets against concerns around input costs and rating downgrades.

Recent updates

No updates